Meng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meng Zhang has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Chuntao Gao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
5 shared publications - Dongqin Zhu
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
5 shared publications - Fenglin Zang
Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
5 shared publications - Hanfei Huang
Organ Transplantation Center, the First Affiliated Hospital of Kunming Medical University
5 shared publications - Hao Zhang
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
5 shared publications - Hongwei Wang
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
5 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file contains supplementary figures illustrating the development and validation of the cfDNA-based pancreatic cancer detection model, including prediction score distributions across clinical subgroups, feature importance analyses, assessments of the limit of detection, and estimated screening benefits. It also includes representative medical imaging and pathological results of the pancreatic cancer related-cases identified in the prospective cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file contains supplementary figures illustrating the development and validation of the cfDNA-based pancreatic cancer detection model, including prediction score distributions across clinical subgroups, feature importance analyses, assessments of the limit of detection, and estimated screening benefits. It also includes representative medical imaging and pathological results of the pancreatic cancer related-cases identified in the prospective cohort.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S8 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file includes supplementary tables summarizing cohort demographics, in silico and empirical estimates of the limit of detection (LOD), model performance across clinical and demographic subgroups, results from the non-pancreatic cancer disease cohort and prospective screening cohort, and simulated clinical impact in hypothetical populations.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S8 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file includes supplementary tables summarizing cohort demographics, in silico and empirical estimates of the limit of detection (LOD), model performance across clinical and demographic subgroups, results from the non-pancreatic cancer disease cohort and prospective screening cohort, and simulated clinical impact in hypothetical populations.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes.Significance:This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management.See related commentary by Tsui and Lo, p. 10
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes.Significance:This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management.See related commentary by Tsui and Lo, p. 10
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Text 1 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This document provides detailed descriptions of patient recruitment procedures for the case-control cohort, methods for genomic feature extraction, model construction and training, statistical analyses, feature importance assessment, and both in silico and experimental evaluations of the limit of detection. It also includes the design of the prospective screening cohort and comprehensive clinical information on the pancreatic cancer–related cases identified therein.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Text 1 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This document provides detailed descriptions of patient recruitment procedures for the case-control cohort, methods for genomic feature extraction, model construction and training, statistical analyses, feature importance assessment, and both in silico and experimental evaluations of the limit of detection. It also includes the design of the prospective screening cohort and comprehensive clinical information on the pancreatic cancer–related cases identified therein.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2501-2511
Risk Factors for Recurrence in Patients with Hepatocellular Carcinoma After Curative Resection or Ablation
Hepatocellular carcinoma (HCC) is the most common liver cancer and has a high incidence in China, largely due to the high prevalence of hepatitis B virus (HBV) infection. HBV‑related HCC often presents with aggressive characteristics but preserved liver function. Resection and ablation are approaches to achieve potentially curative outcomes. However, the recurrence rate is high, with up to 70% within five years. Curative surgery or ablation is used more broadly in China than in Western countries, so identifying patients at high risk of recurrence is essential: risk stratification can inform postoperative management, including surveillance intensity and avoidance of over- or under-treatment. Baseline characteristics provide a simple method of prediction, the impacts of which differ in early and late recurrence. To our knowledge, this is the first narrative review to comprehensively understand the identification, prevalence, and impact of risk factors for both early and late HCC recurrence in Chinese patients following curative‑intent resection or ablation. The review suggests that the most impactful risk factors for early recurrence are aggressive tumor features including tumor size, number and vascular invasion. For late recurrence, key risk factors are patient characteristics such as sex, viral infections and liver cirrhosis. As these risk factors are interrelated, several integrated predictive models like nomograms and artificial intelligence (AI) applications have been proposed, which may enhance risk stratification and inform personalized management strategies. These models should be further validated in large prospective studies to achieve clinical application.
- 1 November 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2501-2511
Open AccessRisk Factors for Recurrence in Patients with Hepatocellular Carcinoma After Curative Resection or Ablation
Hepatocellular carcinoma (HCC) is the most common liver cancer and has a high incidence in China, largely due to the high prevalence of hepatitis B virus (HBV) infection. HBV‑related HCC often presents with aggressive characteristics but preserved liver function. Resection and ablation are approaches to achieve potentially curative outcomes. However, the recurrence rate is high, with up to 70% within five years. Curative surgery or ablation is used more broadly in China than in Western countries, so identifying patients at high risk of recurrence is essential: risk stratification can inform postoperative management, including surveillance intensity and avoidance of over- or under-treatment. Baseline characteristics provide a simple method of prediction, the impacts of which differ in early and late recurrence. To our knowledge, this is the first narrative review to comprehensively understand the identification, prevalence, and impact of risk factors for both early and late HCC recurrence in Chinese patients following curative‑intent resection or ablation. The review suggests that the most impactful risk factors for early recurrence are aggressive tumor features including tumor size, number and vascular invasion. For late recurrence, key risk factors are patient characteristics such as sex, viral infections and liver cirrhosis. As these risk factors are interrelated, several integrated predictive models like nomograms and artificial intelligence (AI) applications have been proposed, which may enhance risk stratification and inform personalized management strategies. These models should be further validated in large prospective studies to achieve clinical application.
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 66-80
Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes. Significance: This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management. See related commentary by Tsui and Lo, p. 10
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 66-80
Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes. Significance: This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management. See related commentary by Tsui and Lo, p. 10
- Open Access
- 22 March 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (3)
New score for prediction of morbidity in patients undergoing open pancreaticoduodenectomy
Objective: The Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) is commonly used to predict the risk of postoperative complications in general surgery. However, use of the POSSUM is not absolutely suitable for open pancreaticoduodenectomy (OPD), which has unique complications such as pancreatic fistula formation. This study was performed to establish a new risk score for assessing the incidence of postoperative complications of OPD. Methods: This retrospective case-control study involved 159 patients who underwent standard OPD from 2 January 2017 to 1 February 2019. The risk factors for post-OPD complications were statistically investigated, and a risk score model was established by multivariate logistic regression. Results: Among all 159 patients, 72 (42.28%) developed complications. A scoring system was developed based on the following five independent variables: sodium concentration of 6.35 × 109/L, pancreatic texture grade, body mass index of >25.06 kg/m2, and basic respiratory diseases. Our risk score model demonstrated better discriminating power, prediction power, and prediction probability than the POSSUM model in the receiver operating characteristic curve analysis. Conclusion: This novel risk score may help to predict postoperative complications after OPD with higher accuracy than the POSSUM system.
- 22 March 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (3)
Open AccessNew score for prediction of morbidity in patients undergoing open pancreaticoduodenectomy
Objective: The Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) is commonly used to predict the risk of postoperative complications in general surgery. However, use of the POSSUM is not absolutely suitable for open pancreaticoduodenectomy (OPD), which has unique complications such as pancreatic fistula formation. This study was performed to establish a new risk score for assessing the incidence of postoperative complications of OPD. Methods: This retrospective case-control study involved 159 patients who underwent standard OPD from 2 January 2017 to 1 February 2019. The risk factors for post-OPD complications were statistically investigated, and a risk score model was established by multivariate logistic regression. Results: Among all 159 patients, 72 (42.28%) developed complications. A scoring system was developed based on the following five independent variables: sodium concentration of 6.35 × 109/L, pancreatic texture grade, body mass index of >25.06 kg/m2, and basic respiratory diseases. Our risk score model demonstrated better discriminating power, prediction power, and prediction probability than the POSSUM model in the receiver operating characteristic curve analysis. Conclusion: This novel risk score may help to predict postoperative complications after OPD with higher accuracy than the POSSUM system.
- Open Access
- 1 September 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (9) , 5517-5527
A newly improved POSSUM scoring system for prediction of morbidity in patients with pancreaticoduodenectomy
Background: Postoperative morbidity of pancreaticoduodenectomy (PD) is still prevalent in hospitals around the world all over the world. Chirurgia B and Chen Yingtai et al. compared the existing POSSUM and p-POSSUM scoring system in pancreatoduodenectomy. However, in this retrospective cohort study our aim was to investigate the risk factors associated with post-PD complications, and develop a POSSUM scoring system more specific to PD, which we define as PD-POSSUM. Methods: Data was gathered from 201 patients who underwent PD procedure at No.4 Hospital of Hebei Medical University between January 2016 and December 2018. All 201 patients were included in the modeling group. The morbidity and associated risk factors were collected and analyzed. The risk factors of complication were investigated by the Pearson χ2 test, Spearman rho test, multivariable linear regression, univariate/multivariate logistic regression. In addition, the discriminating ability of the PD-POSSUM system to predict morbidity is estimated by the area under the receiver operating characteristic curve (ROC-AUC). Results: Morbidity was 45.5% for the 201 patients. Multivariate logistic regression analysis demonstrated a significant connection between postoperative complications and body mass index (BMI) [odd ratio (OR): 3.700; 95% confidence interval (95% CI): 1.594–4.572], pre-existing respiratory diseases (OR: 3.000; 95% CI: 1.542–5.837), international normalized ratio of prothrombin time (OR: 0.321; 95% CI: 0.099–1.038), alanine aminotransferase (OR: 0.573; 95% CI: 0.375–0.874); total bilirubin level (OR: 1.477; 95% CI: 1.068–2.043); diameter of pancreatic duct (OR: 1.837; 95% CI: 1.221–2.763) and diameter of tumor diameter (OR: 1.837; 95% CI: 1.221–2.763). Conclusions: This risk assessment formula can help estimate and predict postoperative morbidity rate after PD.- 1 September 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (9) , 5517-5527
Open AccessA newly improved POSSUM scoring system for prediction of morbidity in patients with pancreaticoduodenectomy
Background: Postoperative morbidity of pancreaticoduodenectomy (PD) is still prevalent in hospitals around the world all over the world. Chirurgia B and Chen Yingtai et al. compared the existing POSSUM and p-POSSUM scoring system in pancreatoduodenectomy. However, in this retrospective cohort study our aim was to investigate the risk factors associated with post-PD complications, and develop a POSSUM scoring system more specific to PD, which we define as PD-POSSUM. Methods: Data was gathered from 201 patients who underwent PD procedure at No.4 Hospital of Hebei Medical University between January 2016 and December 2018. All 201 patients were included in the modeling group. The morbidity and associated risk factors were collected and analyzed. The risk factors of complication were investigated by the Pearson χ2 test, Spearman rho test, multivariable linear regression, univariate/multivariate logistic regression. In addition, the discriminating ability of the PD-POSSUM system to predict morbidity is estimated by the area under the receiver operating characteristic curve (ROC-AUC). Results: Morbidity was 45.5% for the 201 patients. Multivariate logistic regression analysis demonstrated a significant connection between postoperative complications and body mass index (BMI) [odd ratio (OR): 3.700; 95% confidence interval (95% CI): 1.594–4.572], pre-existing respiratory diseases (OR: 3.000; 95% CI: 1.542–5.837), international normalized ratio of prothrombin time (OR: 0.321; 95% CI: 0.099–1.038), alanine aminotransferase (OR: 0.573; 95% CI: 0.375–0.874); total bilirubin level (OR: 1.477; 95% CI: 1.068–2.043); diameter of pancreatic duct (OR: 1.837; 95% CI: 1.221–2.763) and diameter of tumor diameter (OR: 1.837; 95% CI: 1.221–2.763). Conclusions: This risk assessment formula can help estimate and predict postoperative morbidity rate after PD.